02.06.2025 19:40
The German biotechnology company BioNTech has signed an agreement with the American pharmaceutical company BMS for the joint development of the cancer drug BNT327, which includes payments of up to $11.1 billion. Following the news, BioNTech's shares rose by about 20% in early trading, reaching $114.75.
```html
It has been reported that the German biotechnology company BioNTech and the American pharmaceutical company Bristol Myers Squibb (BMS) have signed a collaboration agreement that foresees payments of up to $11.1 billion for the joint development and commercialization of BioNTech's cancer drug in the research phase.
In a joint statement made by BioNTech and BMS, it was stated that the German company has agreed to develop and commercialize the cancer drug BNT327 in collaboration with the American company.
$11 BILLION MEGA DEAL
According to the agreement, BMS will pay BioNTech a total of up to $11.1 billion for the collaboration. BioNTech will receive an upfront payment of $1.5 billion.
SHARES SOARED
Following the news, BioNTech's shares rose by about 20% in early trading, reaching $114.75.
WHAT HAPPENED?
BioNTech developed the COVID-19 vaccine using mRNA technology and launched it in collaboration with the American company Pfizer. BioNTech generated approximately $19 billion in revenue from this mRNA vaccine in 2021.
After the COVID-19 pandemic, BioNTech shifted its focus to developing cancer drugs and aims to launch its first cancer drug in 2026.
```